The U.S. Centers for Medicare & Medicaid Services (CMS) has opted to cover the Freestyle Libre System from Abbott Laboratories for insulin-dependent diabetes patients. The system, which was just approved by the FDA in late September, is the only continuous glucose monitor (CGM) that does not require any user calibration, thereby eliminating the need for routine fingersticks. (See BioWorld MedTech, Sept. 29, 2016.) Read More
